Currently the only therapies approved forthe treatment of PD and AD are agents that attenuate the symptoms (symptomatic) ofthe disease without disease-modifying activity except the anti-Parkinson drugrasagiline (Rasagiline),11which we developed.12 Themainstay for PD treatment focuses on the replacement of lost DA with L-dopa,dopamine agonists, monoamine oxidase B inhibitors, and catechol-O-methyl transferaseinhibitors, thereby normalizing the patient symptomatically;10 while for AD there are the cholinesteraseinhibitors and the glutamate antagonist memantine. This evidence concerns the gene MAOB and Alzheimer disease.